Medtronic Plc Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Medtronic Plc on June 21, 2024, with the earliest event reported on that date. The filing addresses significant changes in executive leadership within the finance function.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. It is a disclosure of corporate governance events rather than a financial results report.
Material Changes
- Resignation of CFO: Karen L. Parkhill, Executive Vice President and Chief Financial Officer, notified the company of her resignation, effective August 2, 2024.
- Appointment of Interim CFO: Gary Corona, currently Senior Vice President, Global Financial Planning and Analysis, was appointed Interim Chief Financial Officer effective upon Ms. Parkhill's departure.
- Background: Mr. Corona joined Medtronic in January 2023. Prior to this, he spent 26 years at General Mills, Inc., most recently as Vice President, Corporate Finance.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, outlook, or management commentary on business performance. It notes that there are no family relationships between Mr. Corona and the company's directors or officers, and no transactions requiring disclosure under Item 404(a) of Regulation S-K. Mr. Corona's compensation arrangements will not change in connection with his interim appointment.
Investor Verification Checklist
- Verify the exact effective date of the CFO transition (August 2, 2024).
- Review the attached press release (Exhibit 99.1) for additional context on the leadership change.
- Monitor future filings for the appointment of a permanent Chief Financial Officer.
- Confirm that no undisclosed compensation arrangements exist for the interim role.